Steve Chen

HBM Partners AG (Investment Management) (HBM-IM) is the asset management division of HBM Partners AG. The firm is headquartered in Zug and was founded in 2001. HBM-IM provides investment advisory services to private companies. They manage the fund HBM Healthcare Investments.

Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001.

Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada.

Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Part of Boston Scientific Corp., Schneider (Europe) GmbH is a Swiss company that makes stents used to prop open arteries and other devices for angioplasty. The company is based in Bulach, Switzerland. Schneider (Europe was acquired by Boston Scientific Corp. from Pfizer Inc. on September 10, 1998 for $2,100 million.

Shape Memory Medical, Inc. develops, manufactures and wholesales novel peripheral vascular and neurovascular embolization devices. The company was founded by Alan R. Pelton and is headquartered in Santa Clara, CA.

Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO.

ValCare Medical, Inc. engages in the designing, developing and commercializing devices and accessories for minimally invasive treatment of heart valve diseases. The firm develops a unique transcatheter device, which will provide the capability to implant the mitral annuloplasty device interventionally without surgery. The company was founded by Samuel M. Shaolian in 2012 and is headquartered in Herzlyia Pituach, Israel.

Tensys Medical, Inc. develops blood pressure monitoring systems. The firm provides patient safety by designing, and manufacturing continuous, non-invasive hemodynamic monitoring systems. The company was founded in 1995 and is headquartered in San Diego, CA.

Vascular Dynamics, Inc. provides blood pressure modulation devices. It develops and commercializes a passive, catheter-delivered implant for the treatment of hypertension. The company was founded in 2008 and is headquartered in Mountain View, CA.

Ellipse Technologies, Inc. develops and commercializes implants for spinal and orthopedic applications. It designs, develop and commercialize non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. The company was founded by Samuel M. Shaolian and Shawn Moaddeb on June 30, 2005 and is headquartered in Aliso Viejo, CA.

Bank Julius Bär & Co. AG (BJB) is the private banking subsidiary of Julius Bär Gruppe AG (SWX: BAER) in Switzerland. Headquartered in Zurich, BJB was founded in 1890 and provides personal wealth management advice to private clients and family offices.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

MiCardia Corp. designs, develops, and commercializes implantable medical devices. The firm offers implantable devices for the treatment of heart diseases, such as mitral valve regurgitation and congestive heart failure. It also provides enCor, an annuloplasty device that corrects residual mitral regurgitation on a beating heart. The company was founded in November 2004 by Michael R. Henson, Shawn Moaddeb and Samuel M. Shaolian and is headquartered in Irvine, CA.

Gebrüder Meier AG is a company based in Regensdorf, Switzerland. The Swiss company provides repair services for electric motors and frequency converters. Part of ERNE AG Bauunternehmung, Gebrüder Meier AG was founded in 1998. Daniel G. Zeidler has been the CEO of the company since 2022.

Reha Technology AG designs, manufactures and distributes robotic-assisted systems for neuro-rehabilitation. Its products include G-EO system, nexstep, first mover and armotion. The company was founded in 2011 and is headquartered in Olten, Switzerland.

Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany.

ConnectRN, Inc. operates as a mobile technology company connecting hospitals with available nurses. Its platform provides various tools to connect healthcare providers to qualified and available staff via an alert system that is sent to their mobile devices. The company is headquartered in Brookline, MA.

Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland.

SCRIPT Biosciences, Inc. develops a genome editing platform. The American company was founded in 2020. Anil Namboodiripad has been the CEO of the company since 2021.

Phifund Managers, LLC (Phifund Managers) is a venture capital firm founded in 2021.The firm is headquartered in New York.

Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020.

Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017.

CoreCommodity Management LLC (CoreCommodity) is a registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Adam de Chiara and Bradford Klein in 2003 as Jefferies Asset Management LLC and changed their name to CoreCommodity Management LLC in 2012. They are a subsidiary of CoreCommodity Capital LLC, which is owned by CoreManagement LLC. CoreCommodity provides investment management services to sovereign wealth funds, public and corporate pensions, endowments and foundations, and other prominent institutional clients seeking commodities exposure.

Knight Capital Group, Inc. is a global financial services firm, which provides access to the capital markets across multiple asset classes to a broad network of clients, including buy and sell side firms, dealers, brokers, institutions, and corporations. It operates business through four segments: Market Making, Institutional Sales and Trading, Electronic Execution Services and Corporate and Other. The Market Making segment consists of market making in global equities and listed domestic options. It includes client, and to a lesser extent, non-client electronic market making activities in which they operate as a market maker in equity securities. The Institutional Sales and Trading segment includes global equity, exchange traded funds and fixed income sales and trading; reverse mortgage origination and securitization; capital markets; and asset management activities. Its business consists of execution and facilitation equities and fixed income transactions as agent on behalf of institutional clients, and they commit capital on behalf of its clients when needed. The Electronic Execution Services segment offers access via its electronic agency-based platforms to markets and self-directed trading in equities, equity options, fixed income, foreign exchange and futures contracts. The Corporate and Other segment invests in strategic financial services-oriented opportunities, allocates, deploys and monitors all capital, and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded in 1995 and is headquartered in Jersey City, NJ.

Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.